AbbVie’s experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company.
Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...
AbbVie (NYSE:ABBV) and its shareholders were dealt a major setback Monday morning after results from a late-stage trial on ...
The company’s announcement on November 11, 2024, revealed that emraclidine’s Phase 2 trials did not achieve their primary objectives, showing lower-than-expected efficacy in reducing PANSS scores, ...
AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback